7.3 Inflammatory Arthropathies (Rheumatoid, Gout, Septic) and Systemic Lupus Erythematosus

Key Takeaways

  • A hot, acutely painful joint with restricted movement warrants urgent assessment for infection. Sample a stable patient's joint before empirical antibiotics when feasible. In sepsis or shock, give antibiotics promptly and arrange aspiration and source control in parallel.

  • Treat gout flares with a suitable anti-inflammatory and continue established allopurinol in an uncomplicated flare. When starting allopurinol, the Irish product information advises waiting until the attack has settled. Titrate to a serum urate target and discuss flare prophylaxis.

  • CPP crystals support CPP crystal arthritis. Urate or CPP crystals can coexist with bacterial infection, so interpret aspiration results with the clinical findings and culture.

  • Persistent small-joint synovitis warrants prompt rheumatology assessment even with negative serology. Anti-CCP supports the diagnosis. Methotrexate for rheumatoid arthritis is taken once weekly with folate and safety monitoring.

  • Use ANA and disease-specific tests to support evaluation of suspected SLE. Polymyalgia rheumatica and giant cell arteritis can coexist. New headache, jaw claudication or visual symptoms in a patient with polymyalgia require urgent assessment. Start high-dose corticosteroid immediately when GCA is strongly suspected.

Last updated: November 2026

Acute monoarthritis and suspected septic arthritis

Acute painful swelling of a joint, especially with marked restriction of passive movement, warrants assessment for infection. Fever can be absent and neither a normal inflammatory marker nor one examination finding excludes infection. Consider Staphylococcus aureus and streptococci, risks for resistant organisms, and gonococcal infection when exposure history or associated tenosynovitis and skin lesions suggest it.

In a stable adult with suspected native-joint infection, obtain an urgent joint aspirate before starting empirical antibiotics when feasible. Use an aseptic approach and avoid passing a needle through an abscess or, where possible, overlying cellulitis. In sepsis or septic shock, start empirical antimicrobials immediately. Draw blood cultures first when this does not meaningfully delay treatment. Arrange aspiration and source control in parallel.

Synovial findingClinical interpretation
WBC above 50,000/µLSupports infection, with overlap with inflammatory and crystal arthritis.
WBC below 25,000/µLLowers the probability. Infection can still be present, particularly when immunosuppressed.
Positive Gram stainHelps guide initial therapy. A negative stain leaves infection possible.
Needle-shaped, negatively birefringent crystalsSupports gout. Infection may coexist.
Rhomboid, weakly positively birefringent crystalsSupports CPP crystal arthritis. Infection may coexist.

Send the fluid for culture, Gram stain, cell count with differential and crystal analysis. Prioritise microbiological identification if the sample is small. Obtain blood cultures if febrile or if bacteraemia or sepsis is suspected. Involve orthopaedics urgently to plan drainage and start empirical IV therapy after sampling in the stable patient. Use local microbiology guidance and tailor therapy to culture and clinical response. Washout is often needed for a large joint. Reassess persistent pain or worsening inflammation for inadequate source control.

EBJIS SANJO native-joint guideline


Crystal Arthropathies: Gout vs Pseudogout (CPPD)

1. Gout (Monosodium Urate)

Gout is caused by deposition of monosodium urate crystals. Higher serum urate increases the likelihood of crystal formation over time. Hyperuricaemia alone cannot establish that acute joint symptoms are due to gout. Kidney disease, diuretics and excess alcohol can contribute. Review the clinical context before changing medicines prescribed for another indication.

An acute flare often causes abrupt severe pain, swelling and erythema. The first metatarsophalangeal joint is a common site (podagra). Tophi can form at the ear, olecranon bursa and Achilles tendon. On compensated polarised microscopy, monosodium urate crystals are usually needle-shaped and strongly negatively birefringent. They appear yellow when parallel to the compensator's slow axis. If gout remains likely despite a serum urate below 360 µmol/L during the attack, NICE advises repeating it at least two weeks after the flare settles.

Pharmacotherapy of Gout: Acute Flare vs Long-Term ULT

Treat acute pain with an NSAID, colchicine or a short course of an oral corticosteroid, chosen for renal function, comorbidities, interactions and patient preference. Continue an established allopurinol dose during an uncomplicated gout flare. Plan any titration after reassessing urate and tolerability. A suspected hypersensitivity reaction requires immediate withdrawal and assessment.

For recurrent or troublesome flares, tophi or other indications for urate-lowering therapy, start low and titrate using serum urate. The Irish Zyloric product information advises starting after an acute attack has fully settled. NICE usually advises waiting two to four weeks after a flare settles and allows starting urate-lowering therapy during a flare when attacks are frequent. The 2020 ACR guideline conditionally favours starting during a flare when the decision to start therapy has already been made. These are guideline differences. The ELAG trial found no significant difference in time to resolution with early versus later allopurinol in its participants.

NICE uses a serum urate target below 360 µmol/L and considers a target below 300 µmol/L for tophi, chronic gouty arthritis or continued frequent flares despite reaching the usual target. Discuss flare prophylaxis during initiation and titration. Colchicine is an option if renal function and interacting drugs permit.

Irish Zyloric product information · NICE NG219 gout recommendations · ACR 2020 gout guideline · ELAG randomised trial

2. Acute calcium pyrophosphate crystal arthritis

Calcium pyrophosphate deposition (CPPD) can present with acute inflammation, chronic joint symptoms or incidental imaging changes. The knee and wrist are common sites in older adults. CPP crystals are often rhomboid and weakly positively birefringent. Radiography or ultrasound can show deposits, for example chondrocalcinosis in the knee meniscus or wrist triangular fibrocartilage. Interpret imaging and crystals with the symptoms and the infection assessment.

Associated conditions include primary hyperparathyroidism, hereditary haemochromatosis and hypomagnesaemia. Consider secondary causes when CPPD appears unusually early or in an atypical pattern. After excluding infection, options for an acute attack include aspiration with intra-articular corticosteroid, or a suitable oral anti-inflammatory. Urate-lowering therapy addresses gout.

ACR/EULAR CPPD classification study · EULAR imaging for crystal-induced arthropathies · EULAR CPPD management recommendations

Rheumatoid arthritis and persistent synovitis

Rheumatoid arthritis (RA) often affects the metacarpophalangeal, proximal interphalangeal, wrist and metatarsophalangeal joints. Symmetric swelling and prolonged morning stiffness support inflammatory arthritis. Early disease may be asymmetric. Distal interphalangeal disease raises other possibilities, such as osteoarthritis or psoriatic arthritis. Late findings can include ulnar drift, swan-neck deformity (PIP hyperextension and DIP flexion) and boutonnière deformity (PIP flexion and DIP hyperextension).

Refer persistent unexplained synovitis promptly. NICE recommends urgent referral when small joints of hands or feet or more than one joint are affected, or presentation was delayed by at least three months. Normal inflammatory markers or negative rheumatoid factor (RF) and anti-CCP results do not justify delaying referral. Anti-CCP is more specific than RF and helps assess risk of erosive disease. Joint findings, alternative diagnoses and other investigations guide diagnosis. Hand and foot radiographs can show marginal erosions and joint-space narrowing as disease progresses.

Worked example. A patient has eight weeks of swollen MCP and wrist joints and prolonged morning stiffness. RF, anti-CCP and CRP are within their reference ranges. Refer urgently for persistent inflammatory synovitis. The clinical pattern still warrants specialist assessment and early treatment.

RA can also involve the eyes, lungs and cervical spine. Consider interstitial lung disease with unexplained breathlessness or dry cough and scleritis with a painful red eye. Atlantoaxial instability can endanger the cord. Neurological symptoms require urgent assessment. Inform anaesthesia of known or suspected cervical disease before airway manipulation so the team can assess imaging and airway needs.

Treat-to-target and medication safety

  • Disease-modifying treatment: Start a conventional DMARD early under specialist care, with methotrexate a usual anchor. Leflunomide or sulfasalazine are alternatives when appropriate. EULAR's 2025 update supports short-term glucocorticoid bridging when needed and adding a biologic when the initial strategy has an inadequate response after three to six months. Choice of treatment depends on activity, comorbidity, prior response and safety risks.
  • Methotrexate: Prescribe a named day once weekly. The BSR recommends folic acid at least 5 mg weekly on a separate day. Check blood count, liver and kidney function before starting and regularly thereafter according to the product and local shared-care schedule. Cytopenias, mouth ulcers, liver injury, and new cough or breathlessness can indicate toxicity. Suspected pneumonitis requires withholding the drug and urgent evaluation, including for infection. Discuss reproductive plans in advance. For example, the Irish methotrexate injection product cited below advises contraception during treatment and for at least six months after treatment for women of childbearing potential, and for at least three months after treatment as a precaution for sexually active men or their partners. Consult the specific product and specialist plan.
  • Other conventional DMARDs: Sulfasalazine needs laboratory monitoring and can reduce sperm counts reversibly. Leflunomide has important reproductive risks and can require an accelerated elimination procedure. Hydroxychloroquine carries a risk of retinopathy. Follow the Irish product label and local ophthalmology pathway. The Irish Plaquenil label calls for a pretreatment eye examination and at least annual follow-up. The Irish Accord product specifies at least six-monthly follow-up. Specialist retinal assessment can use OCT and fundus autofluorescence.
  • Before biologic or targeted therapy: Assess infection risk, vaccination status and hepatitis B status. Assess hepatitis C as appropriate. A latent TB assessment typically includes an interferon-gamma release assay and chest radiograph according to local guidance. A negative test alone cannot rule out active TB.

NICE NG100 rheumatoid arthritis · EULAR RA 2025 update · BSR 2025 conventional DMARD guideline · Irish methotrexate injection product information · Irish Plaquenil product information · Irish Accord product information · EULAR infection screening · Perioperative cervical imaging study

Systemic lupus erythematosus

SLE can cause photosensitive malar rash, oral ulcers, inflammatory joint symptoms, pleuritis or pericarditis, cytopenias, kidney disease and neurological manifestations. A malar rash often spares the nasolabial folds. Seizures and psychiatric symptoms can occur. Assess other possible causes, including infection, medication and metabolic problems. A new neurological syndrome needs organ-specific evaluation.

ANA is a sensitive initial test in the appropriate clinical setting, with limited specificity. Anti-dsDNA and anti-Sm support SLE. Changing anti-dsDNA and complement can support an activity assessment alongside symptoms, examination and organ tests. The 2019 EULAR/ACR criteria use positive ANA as a research classification entry criterion. Clinical diagnosis and treatment require a broader assessment. Antiphospholipid antibodies can be associated with thrombosis and pregnancy morbidity.

Detect lupus nephritis early

Monitor blood pressure, kidney function, urine sediment and protein excretion according to disease activity and risk. New proteinuria, haematuria with cellular casts, hypertension or declining kidney function warrants prompt assessment. In SLE without known renal disease, the ACR recommends checking for proteinuria at least every six to twelve months and with extrarenal flares. Unexplained kidney dysfunction or a urine protein-to-creatinine ratio above 0.5 g/g are examples that warrant specialist consideration of biopsy. Biopsy class and disease severity guide treatment.

Hydroxychloroquine is usual background therapy unless contraindicated. EULAR targets around 5 mg/kg/day of actual body weight, individualised for flare and retinal risk. Organ-threatening disease requires specialist treatment. For active proliferative nephritis, KDIGO combines glucocorticoids with immunosuppression such as a mycophenolate-based regimen or low-dose IV cyclophosphamide. Selected combinations include belimumab or a calcineurin inhibitor. Tailor induction and maintenance to biopsy findings, renal function, reproductive plans and response. Monitor for infection and minimise long-term steroid exposure.

BSR 2026 lupus guideline · 2019 EULAR/ACR SLE classification · EULAR 2023 SLE management · KDIGO 2024 lupus nephritis · ACR lupus nephritis guideline

Polymyalgia rheumatica and giant cell arteritis

Polymyalgia rheumatica (PMR)

PMR typically starts after age 50 and causes bilateral shoulder aching and prolonged morning stiffness, often with hip girdle symptoms and difficulty dressing or rising from a chair. Pain can limit effort. True weakness or a raised creatine kinase suggests evaluating other explanations. ESR and CRP are commonly raised. Consider inflammatory arthritis, myopathy, infection or malignancy when the pattern is atypical.

Check for headache, scalp tenderness, jaw claudication and visual symptoms at presentation and during follow-up. For confirmed isolated PMR, the EULAR 2025 update suggests 15–25 mg/day prednisone equivalent initially. BSR 2026 starts prednisolone at 12.5–15 mg/day in newly diagnosed PMR, with an increase up to 25 mg if needed. Adjust and taper to response and toxicity risk. A prompt improvement supports the working diagnosis, alongside clinical reassessment. Relapse, poor response or substantial glucocorticoid toxicity warrants specialist review.

BSR 2026 polymyalgia rheumatica treatment guideline

Giant cell arteritis (GCA)

GCA is a large- and medium-vessel vasculitis that can coexist with polymyalgia rheumatica. Ask about new headache, scalp tenderness, jaw claudication and diplopia or transient or persistent visual loss. Arteritic anterior ischaemic optic neuropathy can cause irreversible loss.

If GCA is strongly suspected, obtain inflammatory markers and a full blood count where feasible and start high-dose systemic corticosteroid promptly. The BSR initial regimen without ischaemic visual manifestations is oral prednisolone 40–60 mg daily. Acute or intermittent ischaemic visual loss warrants same-day ophthalmology and consideration of IV methylprednisolone 500–1,000 mg daily for up to three days. Start appropriate high-dose oral therapy immediately if IV is delayed.

Arrange urgent rheumatology and early confirmatory testing. The EULAR 2025 update, published in 2026, recommends specialist assessment within 24 hours of suspected GCA. Use temporal and axillary ultrasound when available with suitable expertise, or biopsy as indicated. Diagnostic confirmation must not delay treatment. If a temporal artery biopsy is required, obtain an adequate segment because involvement can be patchy. BSR GCA guideline · EULAR 2025 PMR and large-vessel vasculitis update · EULAR imaging recommendations

Spondyloarthritis patterns

Axial spondyloarthritis

Consider axial spondyloarthritis in persistent back pain beginning before age 45, especially with morning stiffness, night waking and improvement with movement. Ask about psoriasis, inflammatory bowel disease, anterior uveitis and family history. Enthesitis at the Achilles tendon and dactylitis are clues. The pattern can occur in any sex and with a negative HLA-B27 test or normal inflammatory markers.

Assess sacroiliac radiographs and use an inflammatory back-pain MRI protocol when radiographs are nondiagnostic and suspicion persists. MRI can identify active inflammation such as bone marrow oedema. Interpret findings with the clinical picture. Radiographic axial spondyloarthritis includes the established ankylosing spondylitis pattern. Syndesmophytes and extensive fusion are late findings. A painful red eye with photophobia warrants same-day eye assessment for possible acute anterior uveitis.

Exercise and specialist physiotherapy are foundational. An NSAID can improve symptoms if safe. Persistent active disease warrants rheumatology review for targeted therapy. Recurrent uveitis, active inflammatory bowel disease and significant psoriasis affect choice of agent.

Psoriatic arthritis

Consider PsA with inflammatory joint symptoms, dactylitis, enthesitis, nail pitting or onycholysis. Skin disease can be subtle or appear after arthritis. Joint patterns include asymmetric oligoarthritis, distal interphalangeal disease, symmetric polyarthritis and axial disease. Erosions with new bone formation can occur. Assess skin, nails and the full distribution. Persistent peripheral synovitis merits timely treatment. The EULAR approach uses a conventional DMARD early for polyarthritis or oligoarthritis with poor prognostic features. Skin, axial and other disease manifestations guide escalation.

Reactive arthritis

Sterile inflammation can develop after a gastrointestinal or genitourinary infection, including chlamydia. Asymmetric lower-limb arthritis or enthesitis are common clues. Conjunctivitis, urethritis, circinate balanitis and keratoderma can occur. The full classic triad is often absent. Consider disseminated gonococcal infection or another septic joint when clinically plausible.

Treat active infection and arrange partner management when indicated. The HSE uses doxycycline 100 mg twice daily for seven days for uncomplicated chlamydia when suitable. Treat joint inflammation with an appropriate anti-inflammatory and seek rheumatology input when symptoms persist. NICE advises against prolonged antibiotic courses solely for reactive arthritis after the initial infection is treated.

NICE NG65 spondyloarthritis · ASAS/EULAR axial spondyloarthritis guidance · EULAR PsA 2023 update · BASHH reactive arthritis guideline · HSE AMRIC chlamydia guideline

Loading diagram...
Emergency Diagnostic Evaluation and Management of Acute Monoarthritis
Test Your Knowledge

A 48-year-old male with a history of hypertension and obesity presents to the emergency department with a 14-hour history of severe pain, redness, and swelling in his right knee. He is unable to bear weight. On examination, the right knee is markedly warm, erythematous, and tense with a large joint effusion. Both active and passive movements are severely restricted by pain. His temperature is 38.6°C, blood pressure is 132/78 mmHg, and heart rate is 104 bpm. Blood tests demonstrate a white cell count of 16.8 x 10^9/L and a C-reactive protein of 210 mg/L. He is alert and well perfused, with no evidence of organ dysfunction. A clinician can aspirate the knee immediately. What is the next diagnostic step?

A

Obtain a plain radiograph of the knee and discharge the patient on oral colchicine 500 mcg twice daily with outpatient rheumatology follow-up

B

Initiate immediate empirical intravenous flucloxacillin 2 g without joint aspiration to prevent bacteremic dissemination

C

Obtain an urgent aseptic knee aspirate for microbiology, cell count and crystal analysis before starting empirical antibiotics

D

Perform an immediate magnetic resonance imaging (MRI) scan of the right knee to evaluate for occult meniscal tears and cruciate ligament injury

Test Your Knowledge

A 58-year-old male with chronic tophaceous gout presents with an acute, exquisitely painful, erythematous flare of his first right metatarsophalangeal joint (podagra) of 18 hours duration. He has been taking allopurinol 300 mg daily for the past 2 years with excellent compliance. His serum urate during the flare is 340 mcmol/L, and his estimated glomerular filtration rate is 78 mL/min/1.73m^2. He has no history of peptic ulcer disease or cardiovascular failure. What is the most appropriate management of his urate-lowering therapy and acute flare?

A

Stop allopurinol immediately, initiate high-dose intravenous methylprednisolone, and restart allopurinol at 600 mg daily once the pain resolves

B

Double the allopurinol dose to 600 mg daily immediately to dissolve the intra-articular tophus, and withhold anti-inflammatory agents

C

Discontinue allopurinol permanently and initiate probenecid monotherapy without acute anti-inflammatory cover

D

Continue allopurinol at his current maintenance dose of 300 mg daily, and prescribe a short course of an oral NSAID (e.g., naproxen) or colchicine for acute symptom control

Test Your Knowledge

A 72-year-old female presents with a 4-week history of severe bilateral aching and stiffness in her neck, shoulders, and pelvic girdle, which is worst in the morning and lasts for nearly 2 hours. Over the past 36 hours, she has developed a new, throbbing, right-sided temporal headache, tenderness when brushing her hair, and pain in her jaw muscles while chewing solid food. She reports no diplopia or visual loss. Blood tests show an ESR of 88 mm/h and CRP of 64 mg/L. What is the most urgent next step in the clinical management of this patient?

A

Schedule an outpatient temporal artery ultrasound and biopsy within 2 weeks, deferring systemic corticosteroids until histological confirmation is secured

B

Start high-dose oral prednisolone immediately and arrange urgent specialist assessment and early diagnostic confirmation for suspected giant cell arteritis.

C

Prescribe low-dose oral prednisolone 15 mg daily for polymyalgia rheumatica and arrange an MRI brain scan to evaluate for intracranial aneurysm

D

Initiate intravenous broad-spectrum vancomycin and ceftriaxone to treat presumed temporal soft tissue abscess and bacterial osteomyelitis

Sections you finish are checked off in the contents.